You are here: Industry Insights > Keytruda

News List

Financial Report：Merck contractpharma
November 06, 2020
Pharmaceutical sales were up 2% to $11.3 billion in the quarter, driven primarily by growth in oncology and certain hospital acute care products.
Sanofi teams up with MSD to test new oncology treatment pharmatimes
October 30, 2020
Sanofi has entered an agreement with MSD – known as Merck & Co in the US – to collaborate on a phase II trial evaluating its investigational candidate THOR-707 alongside MSD’s immunotherapy Keytruda.
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC europeanpharmaceuticalreview
October 26, 2020
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
ICR urges change as NICE rejects Keytruda plus chemotherapy pharmatimes
October 26, 2020
The Institute for Cancer Research (ICR) has called for change in the way immunotherapy drugs are researched and evaluated after the National Institute for Health and Care Excellence (NICE) handed MSD’s Keytruda plus chemotherapy a rejection.
First Patient Dosed in Trial of LNS8801, KEYTRUDA Combination in Advanced Cancer americanpharmaceuticalreview
October 19, 2020
Linnaeus Therapeutics has dosed the first patient in its phase 1/2 adaptive-design clinical trial of its lead-product-candidate, LNS8801, in combination with KEYTRUDA® (pembrolizumab) in patients who had previous clinical benefit from immune checkpoint...
US FDA approves KEYTRUDA from Merck for adults with relapsed or refractory cHL expresspharma
October 16, 2020
KEYTRUDA is the first anti-PD-1 therapy approved for adult patients with relapsed or refractory cHL after frontline therapy.
Merck’s Keytruda plus chemotherapy meets OS and PFS goals in KEYNOTE-590 trial pharmaceutical-business-review
September 27, 2020
Merck announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of patients ...
Keytruda/Lenvima combo shows promise in hard-to-treat cancers pharmatimes
September 22, 2020
MSD (Merck) and Eisai have revealed new data from two trials under the LEAP clinical programme evaluating the combination of MSD’s PD-1 inhibitor Keytruda and Eisai’s oral tyrosine kinase inhibitor Lenvima.
Vaccinex, Merck Collaborate on Keytruda Combo contractpharma
September 18, 2020
Vaccinex Inc., a clinical-stage biotechnology company, has entered into a clinical collaboration agreement with Merck through a subsidiary, to evaluate the combination of Vaccinex’s investigational SEMA4D inhibitor, pepinemab, and Merck’s anti-PD-1 ...
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta pharmatimes
August 28, 2020
MSD’s Keytruda (pembrolizumab) in combination with Pfizer's Inlyta (axitinib) has been turned down by NICE as first-line treatment for patients with advanced renal cell carcinoma (RCC).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page